Search our Database of Scientific Publications and Authors

I’m looking for a

    1995 results match your criteria Allergy and Asthma Proceedings[Journal]

    1 OF 40

    Randomized trial to assess the efficacy and safety of beclomethasone dipropionate breath-actuated inhaler in patients with asthma.
    • Authors:
    Allergy Asthma Proc 2018 Jan 9. Epub 2018 Jan 9.
    Background: Breath-actuated inhalers (BAI) eliminate the need for the hand-breath coordination required with standardmetered-dose inhalers (MDI).

    Objective: To evaluate the efficacy and safety of beclomethasone dipropionate (BDP) administered via BAI.

    Methods: This 6-week, phase III, double-blind study included patients aged greater than or equal to 12 years with persistent asthma. Read More

    Evaluating satisfaction of patients with hereditary angioedema with their past and present treatments: Implications for future therapies.
    Allergy Asthma Proc 2018 Jan;39(1):74-80
    Background: Ever-expanding armamentarium of treatments for hereditary angioedema (HAE) are associated with various adverse effects, issues with vascular access, or lack of self-administration.

    Objective: To understand patients' impressions and confidence in their past and present treatments, and identifying adverse events while also directly asking patients to reveal their hope for the future of HAE management and treatments.

    Methods: After institutional review board approval, all subjects with laboratory-confirmed HAE were mailed a survey that they completed and returned to the researchers, and data were collected and entered into a secure online web application for surveys. Read More

    Comparison of the effect of 5-grass pollen sublingual immunotherapy tablets and drops in children with rhinoconjunctivitis.
    Allergy Asthma Proc 2018 Jan;39(1):66-73
    Background: One of the most important aspects of sublingual immunotherapy (SLIT) is the regimen of administration.

    Aim: To find any differences in symptom-medication scores between the two groups of SLIT tablets and drops, given pre-coseasonally (starting 8 weeks before the pollen season) in children with rhinoconjunctivitis allergy to grass pollen. The secondary outcome were the differences in lung function and induction of T-regulatory forkhead box P3 (FOXP3) positive cells. Read More

    Characteristics of beef allergy in schoolchildren in Turkey.
    Allergy Asthma Proc 2018 Jan;39(1):59-65
    Background: The prevalence of immunoglobulin E (IgE) mediated beef allergy in childhood is unknown. We investigated the prevalence and characteristics of IgE-mediated beef allergy in urban schoolchildren.

    Methods: This cross-sectional study recruited 6000 randomly selected urban schoolchildren ages 6-17 years from the city center of Giresun in the eastern Black Sea region of Turkey during 2013. Read More

    Heterogeneity of asthma and the risk of celiac disease in children.
    Allergy Asthma Proc 2018 Jan;39(1):51-58
    Background: Although human leukocyte antigen (HLA)-DR and HLA-DQ genes and gluten play crucial roles in developing celiac disease (CD), most patients with these risk factors still do not develop CD, which indicates additional unrecognized risk factors.

    Objective: To determine the association between asthma and the risk of CD in children.

    Methods: We conducted a population-based retrospective case-control study in children who resided in Olmsted County, Minnesota. Read More

    Systemic inflammation mediates the detrimental effects of obesity on asthma control.
    Allergy Asthma Proc 2018 Jan;39(1):43-50
    Background: Obesity negatively impacts asthma control, but the inflammatory mechanisms are poorly understood.

    Objective: To explore which systemic inflammatory mediators mediate the effects of obesity on asthma control.

    Methods: The subjects with stable asthma (n = 108) underwent assessment of clinical characteristics, which included using The Asthma Control Questionnaire (ACQ)-6. Read More

    The effect of omalizumab treatment on the low affinity immunoglobulin E receptor (CD23/fc epsilon RII) in patients with severe allergic asthma.
    Allergy Asthma Proc 2018 Jan;39(1):36-42
    Background: Omalizumab is an anti-immunoglobulin E (IgE) monoclonal antibody used in the treatment of severe asthma. Its therapeutic efficacy is primarily attributed to reduction of serum-free IgE and in the expression of high-affinity IgE receptor, fc epsilon RI. However, its effect on the low-affinity IgE receptor fc epsilon RII/CD23 in vivo has not been evaluated. Read More

    Characterizing patients with asthma who received Global Initiative for Asthma steps 4-5 therapy and managed in a specialty care setting.
    Allergy Asthma Proc 2018 Jan;39(1):27-35
    Background: Severe asthma is recognized in the European Respiratory Society/American Thoracic Society guidelines as a major unmet need in the management of asthma.

    Objective: The study objective was to describe the clinical burden of Global Initiative for Asthma (GINA) steps 4-5 asthma for patients treated by specialists in the U.S. Read More

    A review of the efficacy and safety of once-daily tiotropium Respimat 2.5 micrograms in adults and adolescents with asthma.
    Allergy Asthma Proc 2018 Jan;39(1):14-26
    Background: Despite current guidelines, many patients with asthma remain symptomatic, particularly those intolerant of, unresponsive to, or uncontrolled by long-acting beta 2-agonists (LABAs). Tiotropium bromide, delivered through the Respimat soft-mist inhaler in 2 puffs of 1.25 micrograms each, is approved for the long-term, maintenance treatment of asthma in patients aged ≥6 years. Read More

    Chronic rhinosinusitis with nasal polyps in the elderly: Assessing current evidence.
    Allergy Asthma Proc 2018 Jan;39(1):9-13
    Background: The recently reported prevalence of chronic rhinosinusitis (CRS) among people >60 years old was 4.7%, with CRS emerging as the sixth most common chronic condition in the elderly. There is still a dearth of studies that focused on older patients, however, regarding the characteristics of CRS with nasal polyps (CRSwNP). Read More

    The dilemma of allergy to food additives.
    Allergy Asthma Proc 2018 Jan;39(1):3-8
    Objective: To provide a brief summary on food additives and to outline a practical approach for evaluating subjects suspected of having reactions to food additives.

    Data Sources: Information was derived from selected reviews and original articles published in peer-reviewed journals, supplemented by the clinical experience of the authors.

    Study Selection: Priority was given to studies that used blinded, placebo controlled, oral challenges to confirm adverse reactions to food additives. Read More

    Asthma control, lung function, symptoms, and corticosteroid sparing after omalizumab initiation in patients with allergic asthma.
    • Authors:
    Allergy Asthma Proc 2017 Dec 5. Epub 2017 Dec 5.
    Background: Omalizumab is approved in patients with moderate-to-severe allergic asthma with symptoms uncontrolled, despite the mainstay therapy.

    Objective: Electronic medical records (EMR) were used to increase the knowledge of omalizumab effectiveness in areal-world setting.

    Methods: Patients with uncontrolled moderate-to-severe allergic asthma, ages greater than or equal to 12 years old, initiated on omalizumab (index date), with greater than or equal to 12 months of pre- and postindex data, were identified in an EMR data base. Read More

    Guidance for compassionate restraint of small children to prevent injuries with epinephrine autoinjectors.
    • Authors:
    Allergy Asthma Proc 2017 Nov 29. Epub 2017 Nov 29.
    Background: Without securing a child properly, injuries can happen with the use of pediatric epinephrine autoinjectors(EAI), and lacerations and embedded needles have been reported. Health care providers should ensure that instruction isprovided to parents on how to hold a child during an injection with an EAI.

    Objective: To demonstrate the compassionate restraint of small children during an allergic emergency to ensure the safe useof an EAI. Read More

    The age-related characteristics of adults with asthma who visited emergency departments in Korea from 2007 to 2012.
    • Authors:
    Allergy Asthma Proc 2017 Nov 28. Epub 2017 Nov 28.
    Background: Understanding the patterns of emergency department (ED) visits of patients with asthma is important for disease control and prevention of exacerbations.

    Objective: This study aimed to investigate the characteristics of adult patients who visited EDs because of their asthma.

    Methods: Patients with asthma, ages greater than or equal to 19 years old, who visited 117 EDs throughout Korea between January 2007 and December 2012 were identified in the National Emergency Department Information System (NEDIS) data base using theInternational Classification of Disease, 10th revision, codes J45 (asthma) and J46 (status asthmaticus). Read More

    A review of the efficacy and safety of once-daily tiotropium Respimat 2.5 micrograms in adults and adolescents with asthma.
    • Authors:
    Allergy Asthma Proc 2017 Nov 6. Epub 2017 Nov 6.
    Background: Despite current guidelines, many patients with asthma remain symptomatic, particularly those intolerant of,unresponsive to, or uncontrolled by long-acting beta 2-agonists (LABAs). Tiotropium bromide, delivered through the Respimatsoft-mist inhaler in 2 puffs of 1.25 micrograms each, is approved for the long-term, maintenance treatment of asthma in patients aged greater than or equal to 6 years. Read More

    The role of intravenous access during oral food challenges in food protein-induced enterocolitis syndrome.
    Allergy Asthma Proc 2017 Nov;38(6):467-473
    Background: Food protein-induced enterocolitis syndrome (FPIES) is a non-immunoglobulin E mediated food hypersensitivity syndrome characterized by profuse vomiting and diarrhea, which leads to lethargy, dehydration, and hypotension. Given the potential severity of reactions, resolution of FPIES is confirmed via oral food challenge (OFC) during which intravenous (IV) access is recommended to facilitate IV fluids (IVF) and steroid therapy. Risk factors for IV treatment are not well characterized. Read More

    Health-related quality of life in Danish children with hereditary angioedema.
    Allergy Asthma Proc 2017 Nov;38(6):440-446
    Background: The potentially life-threatening disease hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) can have considerable impact on the health-related quality of life (HRQoL) in adult patients. Half the patients with C1-INH-HAE develop symptoms before the age of 10 years. However, the HRQoL in children with C1-INH-HAE is almost unexplored. Read More

    Management of adverse reactions to biologic agents.
    Allergy Asthma Proc 2017 Nov;38(6):409-418
    Hypersensitivity reactions (HSR) to targeted biologic agents present as immediate reactions during infusion or as delayed reactions (after one or more exposures). The new classification includes phenotypes, endotypes, and biomarkers. Phenotypes include immediate type I (immunoglobulin E [IgE] or non-IgE mediated), cytokine release, mixed (type I/cytokine), and immune complexes type III (IgG mediated) reactions as well as delayed type IV reactions. Read More

    Interleukin 31 and skin diseases: A systematic review.
    Allergy Asthma Proc 2017 Nov;38(6):401-408
    Background: Although the pathophysiology of pruritus has been extensively studied in recent years, with many resultant advancements, management of pruritus is still enigmatic, particularly in chronic cutaneous diseases, such as atopic dermatitis, chronic urticaria, allergic contact dermatitis, cutaneous T-cell lymphoma, and uremic pruritus. The recent finding of the involvement of interleukin (IL) 31 in the pathogenesis of chronic pruritus has provided a novel approach to the management of chronic inflammatory skin disorders. The present report provided an in-depth overview of the role of IL-31 in chronic skin diseases and the possible diagnostic and therapeutic applications in the management of these diseases. Read More

    High adherence to subcutaneous immunotherapy in a real-life study from a large tertiary medical center.
    Allergy Asthma Proc 2017 Nov;38(6):78-84
    Background: Studies on real-life adherence to subcutaneous allergen immunotherapy (SCIT) for respiratory allergy are scarce. The aim of this study was to evaluate adherence to SCIT.

    Methods: The patients prescribed SCIT for allergic rhinitis and/or asthma in 2009-2011 were contacted in 2014 and asked whether they completed at least the 3 years of SCIT and/or whether they suspended the treatment for at least 2 months. Read More

    Association of imbalance of effector T cells and regulatory cells with the severity of asthma and allergic rhinitis in children.
    Allergy Asthma Proc 2017 Nov;38(6):70-77
    Purpose: This study investigated the frequency and absolute numbers of different subsets of peripheral blood cells, including CD4+ T cells and CD19+ interleukin (IL) 10+ B regulatory cells (Breg) and their potential association with clinical laboratory measurements in children diagnosed with simple asthma or asthma plus allergic rhinitis (AR).

    Method: The frequency and numbers of peripheral blood CD4+ interferon (IFN) gamma+ T-helper (Th) type 1, CD4+ IL-4+ Th2, CD4+ IL-17A+ Th17, CD4+CD25+ Forkhead Box P3+ regulatory T cells (Treg) and CD19+ IL-10+ Bregs in 22 children with asthma, 17 children with asthma and AR, and 25 healthy controls were determined by flow cytometry. The levels of serum cytokines were determined by enzyme-linked immunosorbent assay. Read More

    Systemic inflammation mediates the detrimental effects of obesity on asthma control.
    Allergy Asthma Proc 2017 Oct 2. Epub 2017 Oct 2.
    Background: Obesity negatively impacts asthma control, but the inflammatory mechanisms are poorly understood.

    Objective: To explore which systemic inflammatory mediators mediate the effects of obesity on asthma control.

    Methods: The subjects with stable asthma (n = 108) underwent assessment of clinical characteristics, which included usingThe Asthma Control Questionnaire (ACQ)-6. Read More

    Recombinant human C1 esterase inhibitor for acute hereditary angioedema attacks with upper airway involvement.
    Allergy Asthma Proc 2017 Nov 13;38(6):462-466. Epub 2017 Sep 13.
    Background: Recombinant human C1 esterase inhibitor (rhC1-INH) is approved for treatment of hereditary angioedema (HAE) in adolescents and adults. HAE attacks that involve the upper airway can be life threatening, and data on the administration of rhC1-INH for these types of attacks are currently limited.

    Objective: To evaluate the efficacy and safety of rhC1-INH for treatment of acute HAE attacks with upper airway involvement. Read More

    Evaluation of beclomethasone dipropionate (80 and 160 micrograms/day) delivered via a breath-actuated inhaler for persistent asthma.
    Allergy Asthma Proc 2017 Nov 8;38(6):419-430. Epub 2017 Sep 8.
    Background: Breath-actuated inhalers (BAI) may simplify the delivery of inhaled medications compared with other devices.

    Objective: To evaluate the efficacy and safety of beclomethasone dipropionate BAI versus matching placebo in adolescent and adult patients with persistent asthma.

    Methods: This phase III, 12-week, double-blind study enrolled patients with asthma aged ≥12 years who were previously treated with a stable dose of inhaled corticosteroid or noncorticosteroid therapy. Read More

    Efficacy of recombinant human C1 esterase inhibitor for the treatment of severe hereditary angioedema attacks.
    Allergy Asthma Proc 2017 Nov 5;38(6):456-461. Epub 2017 Sep 5.
    Background: Severe attacks of hereditary angioedema (HAE) are debilitating and potentially life threatening, and can increase anxiety and the use of medical resources.

    Objective: This post hoc assessment evaluated recombinant human C1 esterase inhibitor (rhC1-INH) used to treat acute severe HAE attacks.

    Methods: In a double-blind, randomized-controlled trial (RCT), patients with an HAE attack (baseline visual analog scale score of ≥50 mm, with severe attacks defined as ≥75 mm) were randomly assigned to receive rhC1-INH (50 IU/kg for patients who weighed <84 kg; 4200 IU for patients who weighed ≥84 kg) or placebo. Read More

    Health-related quality of life in relation to disease activity in adults with hereditary angioedema in Sweden.
    Allergy Asthma Proc 2017 Nov 30;38(6):447-455. Epub 2017 Aug 30.
    Background: Health-related quality of life (HR-QoL) is impaired in patients with hereditary angioedema (HAE) but has not yet been satisfactorily described.

    Objective: To study HR-QoL in patients with HAE by combining different HR-QoL instruments with disease activity assessment.

    Methods: All adults in the Swedish HAE registry were invited to take part in this questionnaire study, which used the generic HR-QoL instruments, EuroQol 5 Dimensions 5 Level (EQ-5D-5L) and the RAND Corporation Short Form 36 (RAND-36), the disease-specific Angioedema Quality of Life instrument (AE-QoL), the recently introduced Angioedema Activity Score (AAS) form, and questionnaires on sick leave and prophylactic medication. Read More

    Skin rash in a 2-week-old infant.
    Allergy Asthma Proc 2017 09;38(5):390-393
    We presented a case of a male infant with annular patchy rash on his torso since 2 weeks of age. This was initially diagnosed as tinea corporis but did not respond to oral antifungal treatment. Because of the appearance of the rash and a history of a certain disease in a maternal aunt, we suspected the most probable cause of the rash and the diagnosis was confirmed by laboratory testing. Read More

    The risk of autoimmune connective tissue diseases in patients with atopy: A nationwide population-based cohort study.
    Allergy Asthma Proc 2017 Sep;38(5):383-389
    Background: The relationship between autoimmune connective tissue disease (ACTD) and atopy is controversial.

    Objectives: To investigate the risks of ACTDs in patients with atopic triad diseases, including atopic dermatitis, allergic rhinitis, and asthma, by using a nationwide data base.

    Methods: A cohort of 155,311 patients newly diagnosed with atopic dermatitis, allergic rhinitis, or asthma in 2002-2011 was obtained from the Taiwan National Health Insurance Research Database. Read More

    Frequency of selective immediate responders to aminopenicillins and cephalosporins in Turkish children.
    Allergy Asthma Proc 2017 Sep;38(5):376-382
    Background: Beta-lactam antibiotics (BLA) are the most commonly prescribed antibiotics and are responsible for the majority of immediate hypersensitivity reactions to drugs in children. Cross-reactivity is important in hypersensitivity to BLAs because these drugs all share a common beta-lactam structure and some share similar side chains.

    Objective: The aim of this study was to evaluate the clinical characteristics of patients who are diagnosed with immediate-type BLA hypersensitivity and frequency of patients with side chain hypersensitivity, "selective responders. Read More

    Association of aeroallergen sensitization and atopic disease in the Sonoran Desert.
    Allergy Asthma Proc 2017 Sep;38(5):370-375
    Background: Numerous aeroallergens have been associated with the development of asthma, including Alternaria, house-dust mite, and pet dander. Tucson, Arizona, is located in the Sonoran Desert, which has the highest diversity of vegetation of any desert in the world. Given the unique pollen profile in this region, we sought to identify the most common aeroallergens associated with rhinitis and asthma diagnosis in the local adult population. Read More

    Pneumococcal 13-valent conjugate vaccine administration after inferior response to pneumococcal vaccine.
    Allergy Asthma Proc 2017 Sep;38(5):365-369
    Background: The pneumococcal vaccine, a nonconjugated vaccine, may be used to evaluate the integrity of the humoral immune system. Those patients with an inferior response to a nonconjugated vaccine may be vaccinated with a conjugated vaccine, which elicits both a B- and T-cell response.

    Objective: We evaluated the immunogenicity of a conjugated vaccine in patients with inferior responses to a nonconjugated vaccine. Read More

    Der p 1 and Der p 2 specific immunoglobulin E measurement for diagnosis of Dermatophagoides pteronyssinus allergy: A systematic review and meta-analysis.
    Allergy Asthma Proc 2017 Sep;38(5):333-342
    Background: A clinical history of allergic symptoms and a skin-prick test with house-dust mite crude extracts are standard diagnostic procedures for Dermatophagoides pteronyssinus allergy. Specific immunoglobulin E (IgE) responses to Der p 1 and Der p 2 allergens have been used for the diagnosis of D. pteronyssinus allergy; however, evaluation of the diagnostic performance of Der p 1 and Der p 2 specific IgE (sIgE) produced inconsistent findings. Read More

    Pre- and postoperative blood neutrophil-to-lymphocyte and eosinophil-to-lymphocyte ratios in patients with sinonasal polyps: A preliminary investigation.
    Allergy Asthma Proc 2017 Sep;38(5):64-69
    Background: Identifying specific endotypes within the broad picture of chronic rhinosinusitis with nasal polyps (CRSwNP), by using biomarkers for instance, remains a challenge. The prognostic role of the neutrophil-to-lymphocyte ratio (NLR) and the eosinophil-to-lymphocyte ratio (ELR) as potential markers of inflammation has already been discussed.

    Objective: The aim of the present study was to compare NLR and ELR before and after endoscopic sinus surgery (ESS) and nasal mometasone furoate for CRSwNP by stratifying patients by their clinical and histologic features. Read More

    Characteristics of drug-induced anaphylaxis in children and adolescents.
    Allergy Asthma Proc 2017 Sep;38(5):56-63
    Background: Although data on anaphylaxis in the general population exist for different allergens, there is still lack of detailed etiologic data on drug-induced anaphylaxis (DIA), particularly in children.

    Objective: To define the etiology of DIA, to determine the accuracy of drug-related anaphylaxis histories, along with the severity and culprit drug associations among individuals <18 years old.

    Methods: Patients with a history of drug hypersensitivity reaction (DHR) referred to our center between January 2012 and February 2016 were included. Read More

    Indicators of poorly controlled asthma and health-related quality of life among school-age children in the United States.
    Allergy Asthma Proc 2017 Nov 11;38(6):431-439. Epub 2017 Aug 11.
    Background: Poorly controlled asthma has far-reaching effects on school-age children and their parents, but little is known about the national impact on health-related quality of life (HRQoL).

    Objective: To examine HRQoL associated with asthma and indicators of poorly controlled asthma in the United States.

    Methods: This was a cross-sectional analysis of HRQoL among school-age children (age range, 6-17 years) with asthma in the nationally representative 2007-2013 Medical Expenditure Panel Survey (MEPS). Read More

    Efficacy and safety of beclomethasone dipropionate breath-actuated or metered-dose inhaler in pediatric patients with asthma.
    Allergy Asthma Proc 2017 Sep 14;38(5):354-364. Epub 2017 Jul 14.
    Background: Breath-actuated inhalers (BAI) eliminate the need for hand-breath coordination and, therefore, simplify the delivery of inhaled medication.

    Objective: To evaluate the efficacy and safety of beclomethasone dipropionate BAI and metered-dose inhaler (MDI) versus placebo in pediatric patients ages 4-11 years with persistent asthma.

    Methods: In this double-blind, double-dummy, phase III study, 628 children with persistent asthma were randomly assigned (1:1:1:1:1) to twice-daily beclomethasone dipropionate (BAI 80 μg/day, BAI 160 μg/day, MDI 80 μg/day, or MDI 160 μg/day) or to placebo. Read More

    A 28-year-old woman with fever, rash, and pancytopenia.
    Allergy Asthma Proc 2017 Jul;38(4):322-327
    A 28-year-old Hispanic woman was admitted to the hospital with fever, sore throat, arthralgia, and a generalized rash of 2 weeks' duration. Her medical history was significant for various food and medication allergies. Multiple antibiotics were given for suspected infection, and she subsequently developed a new skin rash, acute liver injury, eosinophilia, and pancytopenia. Read More

    Pearls and pitfalls: Autoimmune lymphoproliferative syndrome and autoimmune lymphoproliferative syndrome-like disease.
    Allergy Asthma Proc 2017 Jul;38(4):317-321
    A case of autoimmune lymphoproliferative syndrome (ALPS) was presented, followed by a discussion of the clinical characteristics, pathophysiology, diagnosis, and management of this disease. Clinical pearls and pitfalls are emphasized for the use of the practicing allergist and the fellow in-training. The diagnosis of ALPS was guided by published criteria. Read More

    A 10-year experience of a novel and safe modified environmental rush immunotherapy protocol.
    Allergy Asthma Proc 2017 Jul;38(4):309-316
    Background: Allergen immunotherapy (AIT) is an effective treatment option for allergic rhinitis. Although conventional AIT takes 6 months to reach maintenance dosing, rush AIT accelerates the build-up period and reaches the maintenance dose months earlier. However, accelerated schedules of AIT carry an increased risk of systemic reactions (SR). Read More

    1 OF 40